

Special Issue

Combined Treatments and Therapies to Cure Spinal Cord Injury

Message from the Guest Editor

Spinal cord injury (SCI) is a rare disease of the central nervous system (CNS), most often originating from trauma following road accidents, falls or violence, causing the loss of motor, sensory and autonomic functions. To date, there is no curative treatment that can be offered to injured patients. Many treatments have been tested to allow tissue and functional recovery after SCI. However, the complexity of the injury suggests that a single treatment is not sufficient to induce real benefits in humans. Therefore, it is thought that only the use of combination therapies would be effective in promoting recovery after SCI, although the ideal combination remains to be determined. We cordially invite you to contribute to this Special Issue. Our aim is to provide most relevant information concerning innovative treatment modalities and their combinations as potential innovative treatments after SCI. Original investigations and review articles are both welcome.

- spinal cord injury
- tissue repair
- functional recovery
- combined treatments
- innovative therapy
- glial scar
- inflammation
- axonal regrowth

Guest Editor

Dr. Nicolas Guerout

SPPIN - Saints-Pères Paris Institute for the Neurosciences - CNRS
UMR 8003, Université Paris Cité, F-75006 Paris, France

Deadline for manuscript submissions

closed (15 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/117890

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).